SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

Share Price is delayed by 15 minutes
Get Live Data
3.75    0.00 (0.00%)
Bid:
3.50
Ask:
4.00
Spread: 0.50 (14.286%)
Market Cap: £1.04m
SNT Live PriceLast checked at - London Stock Exchange

Intraday Sabien Tech. Share Chart

Issue of Equity

10 Jan 2020 13:30

RNS Number : 4848Z
Sabien Technology Group PLC
10 January 2020
 

For immediate release

10 January 2020

Sabien Technology Group plc

("Sabien" or the "Company")

Issue of equity

The Board of Sabien is pleased to announce that the placing of 200,000,000 new ordinary shares (the "Placing Shares") with new and existing investors, at a price of 0.15 pence per Placing Share (the "Placing Price") was approved by shareholders at the General Meeting held on 8 January 2020 and the Placing Shares commenced trading on AIM with effect from 9 January 2020 (the "Placing").

As previously announced, the Company's largest shareholder, Truell Intergenerational Family Limited Partnership ("TIG"), subscribed for 20,000,000 Placing Shares at the Placing Price and is now interested in 316,751,623 ordinary shares representing 22.84 per cent. of the enlarged issued share capital. TIG had previously been interested in 25.0 per cent. of the Company's issued share capital and had expressed an interest to subscribe for further new ordinary shares at the Placing Price to maintain its interest at 25.0 per cent. The Board of Sabien has now agreed today to issue 46,666,667 new ordinary shares at the Placing Price to TIG ("Subscription"). Following completion of the Subscription and the further issue of equity set out below, TIG will be interested in 25.0 per cent. of the enlarged issued share capital.

The proceeds of the Subscription amount to £70,000 and will be used to provide additional working capital for the continued development of the Company, in line with its stated strategy. Together with existing cash balances (including the proceeds of the Placing) the Company's current cash balances will amount to approximately £820,000. In order to maximise the Company's cash funds available for new investment, the Board has also agreed today to settle accrued but unpaid directors fees due to Cédriane de Boucaud Truell and Marco Nijhof (amounting to £15,000 each) in new ordinary shares ("Fee Shares"), also to be issued at the Placing Price. Accordingly, the Board has issued 10,000,000 new ordinary shares to each of Cédriane de Boucaud Truell and Marco Nijhof (neither of whom previously held any ordinary shares), and who will each be interested in 0.69 per cent of the enlarged issued share capital of the Company.

Once issued, the Subscription Shares and the Fee Shares (together the "New Shares") will rank pari passu with the Company's existing ordinary shares. Application will be made for the New Shares to be admitted to trading on AIM ("Admission") on or around 16 January 2020. The New Shares in aggregate represent 4.8 per cent. of the current issued share capital of the Company.

Richard Parris said:

"These additional funds further strengthen the Company's position to respond to possible business opportunities and broadens the alignment of Directors interests with those of our shareholders."

Total Voting Rights

In conformity with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("FCA") Sabien announces that as at today's date the Company's issued share capital consists of 1,453,673,157 Ordinary Shares of 0.01p each with voting rights. The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights is 1,453,673,157.

The above figure of 1,453,673,157 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Special note concerning the Market Abuse Regulation

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 ("MAR").

The person who arranged for the release of this announcement on behalf of the Company was Richard Parris, Executive Chairman.

For further information:

Sabien Technology Group plc

Richard Parris and Cédriane de Boucaud Truell

+44(0)20 7993 3700

Beaumont Cornish Limited (Nominated Advisor)

Michael Cornish and Roland Cornish

www.beaumontcornish.com

+44(0)20 7628 3396

Peterhouse Capital Limited (Broker)

Duncan Vasey and Lucy Williams

+44(0)20 7469 0930

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Cédriane de Boucaud Truell

2

 

Reason for the notification

 

a)

 

Position/status

 

Director

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Sabien Technology Group plc

b)

 

LEI

 

213800S5QG1SMGHFHY68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.01p each ("Ordinary Shares")

 

Identification code

ISIN: GB00B1FPCD38

 

b)

 

Nature of the transaction

 

Settlement of directors' fees in Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volumes(s)

£0.15

10,000,000

 

 

 

d)

 

Aggregated information

n/a

- Aggregated volume

- Price

e)

 

Date of the transaction

 

10 January 2019

f)

 

Place of the transaction

 

London Stock Exchange

XLON

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Marco Nijhof

2

 

Reason for the notification

 

a)

 

Position/status

 

Director

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Sabien Technology Group plc

b)

 

LEI

 

213800S5QG1SMGHFHY68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.01p each ("Ordinary Shares")

 

Identification code

ISIN: GB00B1FPCD38

 

b)

 

Nature of the transaction

 

Settlement of directors' fees in Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volumes(s)

£0.15

10,000,000

 

 

 

d)

 

Aggregated information

n/a

- Aggregated volume

- Price

e)

 

Date of the transaction

 

10 January 2019

f)

 

Place of the transaction

 

London Stock Exchange

XLON

 

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEKKKBDNBKDBDD
Date   Source Headline
9th Jan 20247:00 amRNSTrading Update
29th Nov 20231:00 pmRNSResult of AGM
29th Nov 20237:30 amRNSAGM Statement
21st Nov 20231:30 pmRNSHolding(s) in Company
3rd Nov 20234:50 pmRNSHolding(s) in Company
2nd Nov 20231:34 pmRNSHolding(s) in Company
2nd Nov 20237:00 amRNSFinal Results & Annual Report & Accounts for 2023
1st Nov 20237:15 amRNSUpdate on 2023 Audited Accounts
4th Oct 20237:00 amRNSM2G Rollout in US
26th Sep 20237:00 amRNSProton Technologies
22nd Sep 20236:00 pmRNSHolding(s) in Company
6th Jul 20237:00 amRNSTrading Update
8th Jun 20237:00 amRNSM2G Business Update
16th May 20237:00 amRNSFurther update on b.grn and related matters
17th Apr 20237:00 amRNSUpdate on b.grn
13th Apr 20239:15 amRNSHolding(s) in Company
6th Apr 20237:00 amRNSDirector/PCA Shareholding
5th Apr 20235:00 pmRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSInterim Results for the 6 months to 31 Dec 2022
28th Mar 20237:00 amRNSMaterial M2G Order & Business Update
27th Mar 20237:00 amRNSM2G supports Empiric on net zero goals
10th Mar 202311:33 amRNSHolding(s) in Company
10th Mar 202311:30 amRNSHolding(s) in Company
10th Mar 20237:00 amRNSMaterial M2G order and M2G trading update
28th Feb 20232:45 pmRNSHolding(s) in Company
6th Feb 20234:30 pmRNSHolding(s) in Company
2nd Feb 20234:51 pmRNSHolding(s) in Company
22nd Nov 202212:00 pmRNSResult of AGM
22nd Nov 20227:30 amRNSInvestor Update & Annual General Meeting Statement
18th Nov 20221:46 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSInvestor Update Presentation
2nd Nov 20227:00 amRNSSupply of UK's First Regenerative Green Oil System
24th Oct 20227:00 amRNSOrder Update – New Channel Partner & Customer
17th Oct 20222:47 pmRNSHoling(s) in Company
17th Oct 20221:54 pmRNSHolding(s) in Company
17th Oct 20227:00 amRNSHoling(s) in Company
17th Oct 20227:00 amRNSInternational Environmental Trae Summit Upate
17th Oct 20227:00 amRNSInternational Environmental Trade Summit Update
17th Oct 20227:00 amRNSHolding(s) in Company
14th Oct 20227:00 amRNSFinal Results for the Year to 30 June 2022
12th Oct 20227:00 amRNSHolding(s) in Company
5th Oct 20223:33 pmRNSHolding(s) in Company
23rd Sep 20222:49 pmRNSHolding(s) in Company
20th Sep 20224:16 pmRNSHolding(s) in Company
16th Sep 20227:00 amRNSRevised Date for Summit for S'th Korean Delegation
31st Aug 20225:00 pmRNSTotal Voting Rights
25th Aug 20223:30 pmRNSAdmission to trading of new Ordinary Shares
22nd Aug 20226:24 pmRNSResult of General Meeting
19th Aug 20227:00 amRNSSales Channel Partnership
16th Aug 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.